Source:http://linkedlifedata.com/resource/umls/id/C1665688
PDQ: A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486626&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=486626&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61502" NCI Thesaurus),NCI: A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab sel